Comparing the Safety and Effectiveness of Glimepiride and Sitagliptin with Metformin in People with Type 2 Diabetes

Comparative evaluation of safety and efficacy of Glimepiride and Sitagliptin in combination with Metformin in patients with Type 2 Diabetes Mellitus - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094759

Enrollment

155

Registered

2025-09-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: Nil: Nil Intervention2: Sitagliptin and metformin: Sitagliptin 100 mg per day Metformin 500-2 g per day for 6 months Control Intervention1: Glimepiride and Metformin: Glimepiride 1-2 m

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged 18 to 65 years with Type 2 Diabetes mellitus FBS and PPBS values more than 100 mg per dl and 140 mg/dl respectively HbA1c levels between more than 7% Patients giving written informed consent will be taken

Exclusion criteria

Exclusion criteria: Type 1 diabetes or secondary diabetes. History of severe hypoglycemia or hypersensitivity to study drugs Significant comorbid conditions such as renal impairment eGFR less than 30 mL per min per 1.73 m , liver dysfunction, or cardiovascular diseases. Pregnant or lactating women. Not giving consent

Design outcomes

Primary

Measure	Time frame
Change in HbA1c levels from baseline to 6 months . Incidence of hypoglycemiaTimepoint: 0, 1, 3, 5, and 6 month	—

Secondary

Measure	Time frame
Change in fasting plasma glucose Changes in body weight Patient reported tolerability & complianceTimepoint: 0, 1, 3, 5, & 6 month	—

Countries

India

Contacts

Public ContactDr Yasha Khan

B R D Medical College

Dranilk194@gmail.com8303060884

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026